Citation Impact
Citing Papers
A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A
1994
Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery
2000
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
2013 Standout
The transfusion-associated transmission of parvovirus B19
1999
Parvovirus B19 Clearance from Peripheral Blood after Acute Infection
1995
Heat stability of parvovirus B19: Kinetics of inactivation
1992
Bone substitutes: An update
2005 Standout
Viral Safety of Blood Derivatives by Immune Neutralization
1998
Parvovirus B19 infection and bone marrow transplantation
1992
2 B19 parvovirus
1995
Human parvovirus B19 infection in bone marrow transplantation patients
1993
Prevalence of Antibodies against Parvovirus B19 in Norwegians with Congenital Coagulation Factor Defects Treated with Plasma Products from Small Donor Pools
1991
Transfusion Medicine — Blood Transfusion
1999 Standout
Parvovirus B19 Infection in Pregnancy
1998
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
2001 Standout
Incidence of human parvovirus B19 DNA detection in blood donors
1995
Nucleic acid testing: Update and applications
2001
The obstetric and gynaecological management of women with inherited bleeding disorders – review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization
2006
Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion
1997
Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors
1993
Human parvoviruses: implications for transfusion medicine
1994
Molecular, cellular and clinical aspects of Parvovirus B19 infection
1994
Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses
2007
Parvovirus B19 for the hematologist
1992
B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates
1994
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Parvovirus B19
2004 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction
1993
Human Parvovirus B19
2002 Standout
Pharmacokinetics of Coagulation Factors
2001
Association of Parvovirus B19 Genome in Children With Myocarditis and Cardiac Allograft Rejection
1997
Occupational Risk of Human Parvovirus B19 Infection for School and Day-care Personnel During an Outbreak of Erythema Infectiosum
1990
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
1999 Standout
New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product
2018 StandoutNobel
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor
1995
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
2001
Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants
1995
Transmission of the hepatitis-C virus by tissue transplantation.
1995
Guidelines for the management of hemophilia
2012 Standout
WFH Guidelines for the Management of Hemophilia, 3rd edition
2020 Standout
Works of M. Morfini being referenced
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization
1997
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates
1988
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates
1992
Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction
1992
Prospective study of the evaluation of hepatitis C virus infectivity in a high‐purity, solvent/detergent‐treated factor VIII concentrate: parallel evaluation of other markers for lipid‐enveloped and non‐lipid‐ enveloped viruses.
1993
Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)
1992